FDA Grants Priority Review to Sotatercept for Pulmonary Arterial Hypertension
Granted a PDUFA date in March 2024, if approved, sotatercept would be a first-in-class medication to address the rare and progressive disease.
Source: hcplive.com
Mariusm Hoeper News Today : Breaking News, Live Updates & Top Stories | Vimarsana
Stay updated with breaking news from Mariusm Hoeper. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Top News In Mariusm Hoeper Today - Breaking & Trending Today
Sotatercept Tied to Disease Modification in PAH
Data show sotatercept may deliver significant clinical benefits and could reshape the trajectory of this challenging disease.
Source: medscape.com
Merck Presents New Analyses Supporting the Promising Potential of Sotatercept, its Investigational Medicine for Adults with Pulmonary Arterial Hypertension (PAH)
Interim results from SOTERIA open-label extension study represent longest safety and efficacy analysis of sotatercept to date; safety profile of sotatercept consistent with previous studies and efficacy improvements maintained after one year of therapy
Source: dicardiology.com
Merck Presents New Analyses Supporting the Promising Potential of Sotatercept, its Investigational Medicine for Adults with Pulmonary Arterial Hypertension (PAH)
Exploratory post-hoc analysis of STELLAR shows potential of sotatercept to improve cardiovascular function Interim results from SOTERIA open-label extension study represent longest safety and...
Source: marketscreener.com
ACC: Sotatercept Boosts Exercise Capacity With Pulmonary Arterial Hypertension
FRIDAY, March 10, 2023 (HealthDay News) -- Sotatercept is associated with a greater improvement in exercise capacity than placebo among patients with pulmonary arterial hypertension (PAH) receiving stable background therapy, according to a study published online March 6 in the New England Journal of Medicine to coincide with the annual meeting of the American College
Source: physiciansweekly.com